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Development of machine learning solutions for prediction of functional and clinical
significance of cancer driver genes and mutations are paramount in modern biomedical
research and have gained a significant momentum in a recent decade. In this work, we
integrate different machine learning approaches, including tree based methods, random
forest and gradient boosted tree (GBT) classifiers along with deep convolutional neural
networks (CNN) for prediction of cancer driver mutations in the genomic datasets. The
feasibility of CNN in using raw nucleotide sequences for classification of cancer driver
mutations was initially explored by employing label encoding, one hot encoding, and
embedding to preprocess the DNA information. These classifiers were benchmarked
against their tree-based alternatives in order to evaluate the performance on a relative
scale. We then integrated DNA-based scores generated by CNN with various categories
of conservational, evolutionary and functional features into a generalized random forest
classifier. The results of this study have demonstrated that CNN can learn high level
features from genomic information that are complementary to the ensemble-based
predictors often employed for classification of cancer mutations. By combining deep
learning-generated score with only two main ensemble-based functional features, we
can achieve a superior performance of various machine learning classifiers. Our findings
have also suggested that synergy of nucleotide-based deep learning scores and
integrated metrics derived from protein sequence conservation scores can allow for
robust classification of cancer driver mutations with a limited number of highly informative
features. Machine learning predictions are leveraged in molecular simulations, protein
stability, and network-based analysis of cancer mutations in the protein kinase genes
to obtain insights about molecular signatures of driver mutations and enhance the
interpretability of cancer-specific classification models.
Keywords: cancer driver mutations, machine learning classifiers, ensemble-based machine learning features,
random forest, deep learning, convolutional neural networks, drug discovery
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INTRODUCTION
Deep sequencing studies have enabled a detailed characterization
of cancer genomes and unveiled important gene-
specific signatures of somatic mutations (Davies et al., 2002;
Bardelli et al., 2003; Futreal et al., 2004; Samuels et al., 2004;
Stephens et al., 2004, 2005; Wang et al., 2004; Sjoblom et al.,
2006; Greenman et al., 2007; Wood et al., 2007; Vogelstein et al.,
2013; Watson et al., 2013). The steadily growing amount of
data generated in cancer genomic studies and next-generation
sequencing (NGS) have been the impetus behind formation of
international cancer genomic projects and development of large
bioinformatics data resources such as Cancer Genome Atlas
(TCGA), Genomics Data Commons Portal (https://portal.gdc.
cancer.gov/) (Weinstein et al., 2013; Jensen et al., 2017), COSMIC
database (http://cancer.sanger.ac.uk) (Forbes et al., 2015), and
the International Cancer Genome Consortium (ICGC) (Hudson
et al., 2010; Zhang et al., 2011; Klonowska et al., 2016; Hinkson
et al., 2017). The Cancer Gene Census of the Catalog of Somatic
Mutations in Cancer (COSMIC) database has grown from 291
well-characterized cancer genes (Futreal et al., 2004) to more
than 500 entries (Forbes et al., 2015) where some cancer genes
can be commonly mutated across cancer types, while other genes
are predominantly cancer-specific. The cBio Cancer Genomics
Portal (https://www.cbioportal.org/) is an open-access resource
for exploration of large cancer genomics data sets (Cerami
et al., 2012; Gao et al., 2013). These datasets have allowed for
comprehensive genome-wide analyses of genetic alterations in
multiple tumor types (Poulos andWong, 2018). A relatively small
fraction of somatic variants known as driver mutations have
considerable functional effects and can be acquired over time as
a result of a range of mutational processes, rather than inherited
(Haber and Settleman, 2007; Lawrence et al., 2013; Vogelstein
et al., 2013). A comprehensive analysis of cancer driver genes and
mutations has provided classification of 751,876 unique missense
mutations, producing a dataset of 3,442 functionally validated
driver mutations (Bailey et al., 2018). Another significant dataset
of 1,049 experimentally tested and functionally validated driver
mutations (Ng et al., 2018) has expanded our knowledge of
cancer-causing variants in oncogenes and tumor suppressor
genes. TCGA organized the Multi-Center Mutation Calling in
Multiple Cancers (MC3) network project which generated a
comprehensive and consistent collection of somatic mutation
calls for the 10,437 tumor samples dataset (Ellrott et al., 2018).
Computational approaches that assess the impact of somatic
mutations are often characterized by different basic assumptions,
types of input information, models, and prediction targets such
as driver gene or driver mutation (Gonzalez-Perez et al., 2013;
Cheng et al., 2016).
A number of somatic variant callers based on various
statistical and machine learning approaches are now available
for somatic mutation detection, including MuTect2 (Cibulskis
et al., 2013), MuSE (Fan et al., 2016), VarDict (Lai et al., 2016),
VarScan2 (Koboldt et al., 2012), Strelka2 (Kim et al., 2018),
SomaticSniper (Larson et al., 2012), and SNooPer (Spinella et al.,
2016). A deep convolutional neural network (CNN) approach
termedDeepVariant can identify genetic variation inNGS data by
discerning statistical relationships around putative variant sites
(Poplin et al., 2018). To facilitate systematic and standardized
somatic variant refinement from cancer sequencing data, random
forest (RF) models and deep learning (DL) approach were
utilized, showing that these machine learning techniques could
achieve high and similar classification performance across all
variant refinement classes (Ainscough et al., 2018). A machine
learning approach called Cerebro increased the accuracy of
calling validated somatic mutations in tumor samples and
outperformed several other somatic mutation detection methods
(Wood et al., 2018).
Many computational methods have been proposed for
prediction of cancer driver genes. Some of these approaches
use cohort-based analysis to detect driver genes, including
ActiveDriver (Reimand and Bader, 2013), MutSigCV (Lawrence
et al., 2013), MuSiC (Dees et al., 2012), OncodriveCLUST
(Tamborero et al., 2013), OncodriveFM (Gonzalez-Perez and
Lopez-Bigas, 2012), and OncodriveFML (Mularoni et al., 2016).
The success of hybrid methods for scoring coding variants
has indicated that integration of different tools may enhance
predictive accuracy for both coding and non-coding variants (Li
et al., 2015). A deep learning-basedmethod (deepDriver) predicts
driver genes by CNN trained with mutation-based feature matrix
constructed using similarity networks (Luo et al., 2019). Since
many methods are often found to predict distinct or partially
overlapping subsets of cancer driver genes, a consensus-based
strategy was recently proposed, showing considerable promise
and outperforming the individual approaches (Bertrand et al.,
2018). A unified machine learning-based evaluation framework
for analysis of driver gene predictions compared the performance
of these methods, showing that the driver genes predicted by
individual tools can vary widely (Tokheim C. et al., 2016;
Tokheim C. J. et al., 2016).
Computational methods designed to identify driver mutations
have become increasingly important to facilitate an automated
assessment of functional and clinical impacts (Gnad et al.,
2013; Ding et al., 2014; Martelotto et al., 2014; Raphael
et al., 2014; Cheng et al., 2016). Functional computational
prediction methods include Sorted Intolerant From Tolerant
(SIFT) (Sim et al., 2012), PolyPhen-2 (Adzhubei et al., 2010),
Mutation Assessor (Reva et al., 2011), MutationTaster (Schwarz
et al., 2010), CONsensus DELeteriousness score of missense
mutations (Condel) (Gonzalez-Perez and Lopez-Bigas, 2011),
Protein Variation Effect Analyzer (PROVEAN) (Choi et al.,
2012), and Functional Analysis Through Hidden Markov
Models (FATHMM) (Shihab et al., 2013). Cancer-specific High-
throughput Annotation of Somatic Mutations (CHASM) (Carter
et al., 2009; Douville et al., 2013; Masica et al., 2017),
Cancer Driver Annotation (CanDrA) (Mao et al., 2013), and
FATHMM (Shihab et al., 2013). Many new approaches have
recently addressed a problem of locating driver mutations
within the non-coding genome regions (Piraino and Furney,
2016). The identification of cancer mutation hotspots in protein
structures has been a fruitful approach for identifying driver
mutations (Dixit et al., 2009; Dixit and Verkhivker, 2011; Gao
et al., 2013; Gauthier et al., 2016; Niu et al., 2016; Tokheim
C. et al., 2016; Tokheim C. J. et al., 2016). To consolidate
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functional annotation for SNVs discovered in exome sequencing
studies, a database of human non-synonymous SNVs (dbNSFP)
was developed (Liu et al., 2011, 2013, 2016; Dong et al.,
2015; Wu et al., 2016). This resource allows for computation
of a total of 48 functional prediction scores for each SNV,
including 32 functional prediction scores by 13 approaches
and 15 conservation features (Wu et al., 2016). In our recent
investigation, two cancer-specific machine learning classifiers
were proposed that utilized 48 functional scores from dbWGFP
server in classification of cancer driver mutations (Agajanian
et al., 2018).
In this work, we explore and integrate RF and DL/CNN
machine learning approaches for prediction and classification
of cancer driver mutations. We first explore the ability of CNN
models to identify and classify cancer driver mutations directly
from raw nucleotide sequence information without relying on
specific functional scores. The performance of these classifiers
was compared to RF and gradient boosted tree (GBT) methods
to provide a comparative analysis of various classification
models. These raw sequence-derived scores are advantageous
because they can be obtained for any mutation with a known
chromosome and position, whereas the functional scoring
features can be limited to subsets of genomic mutations. By
developing a successful classification scheme that could leverage
information from rawDNA sequences, the universe of classifiable
mutations can be greatly expanded leading to more general and
robustmachine learning tools. The results of this study reveal that
CNN models can learn high importance features from genomic
information that are complementary to the ensemble-based
predictor scores traditionally employed in machine learning
classification of cancer mutations. We show that integration
of the DL-derived predictor score with only several ensemble-
based features can recapitulate the results obtained with a
large number of functional features and improve performance
in capturing driver mutations across a spectrum of machine
learning classifiers. Machine learning predictions are leveraged
in biophysical simulations and network analysis of protein kinase
oncogenes to obtain more detailed functional information about
molecular signatures of activating driver mutations, aiding in the
interpretability of cancer mutation classifiers.
MATERIALS AND METHODS
Mutational Datasets and Feature Selection
In our earlier study (Agajanian et al., 2018) we used RF
classifier to predict cancer driver mutations using a combination
of two golden datasets (Mao et al., 2013; Martelotto et al.,
2014). Here, we expanded this dataset by adding the predicted
cancer driver mutations and passengers from the analysis
of missense mutations in Cbioportal database (Agajanian
et al., 2018). By leveraging the earlier analysis, we created a
dataset consisting of functionally validated 6,389 cancer driver
mutations and 12,941 passenger mutations. The driver/passenger
classifications for 2,570 of these mutations were present in the
two aforementioned golden datasets, and our RF classifier made
predictions on the remaining 16,760 missense mutations from
the Cbioportal database. Given the performance level of our
model (Agajanian et al., 2018), we conjectured that a combination
of the two golden datasets and the missense mutations in
the Cbioportal database would yield an informative dataset
for the current study. The initially selected features for RF
predictions were obtained from dbWGFP web server (Wu et al.,
2016) of functional predictions for human whole-genome single
nucleotide variants (Supplementary Table S1). A total of 32
sequence-based, evolutionary and functional features identified
in our previous study (Agajanian et al., 2018) were initially
used for machine learning experiments with the new dataset
of cancer mutations. In cancer driver mutation predictions,
traditional input data contain distinct features that cannot be
directly applied to CNN models due to their lack of spatial
meaning. Using the chromosome and the position on that
chromosome that corresponded to the mutated nucleotide, we
could retrieve the surrounding nucleotides of the mutation of
interest to perform classification with only this raw string of
nucleotides. To represent the original nucleotide and its mutated
version, we placed two nucleotide sequences on top of each other,
one containing the original string, and the other contained the
mutated version. This would only result in a one nucleotide
difference between the two, allowing to effectively utilizing the
sliding window format of the CNN models. The schematic
workflow diagram of the CNN approach employed in this study
is presented in Figure 1.
To create this dataset, we parsed information from
University of California, Santa Cruz (UCSC) Genome Browser
(http://genome.ucsc.edu/) (Tyner et al., 2017) which takes a
chromosome (CHR) and a position (POS) on that chromosome
as arguments and returns back all nucleotides within the
sequence. Using the dataset consisting of 6,389 driver mutations
and 12,941 passengers, we created 5 different datasets of various
window sizes around each given CHR/POS pair. The explored
window sizes (10, 50, 100, 500, and 5,000) produced nucleotide
strings of length 21, 101, 201, 1,001, and 10,001, respectively.
To represent the type of mutation (A->C, A->G, etc.) we
stacked two of the same nucleotide sequences on top of each
other, having one contain the original nucleotide at the position
passed in initially, and the other containing the mutated version
(Figure 2A). This operation resulted in a total input matrix size
of (2, 21), (2, 101), (2, 201), (2, 1001), and (2, 10001), respectively.
Three different preprocessing techniques were then applied to
the dataset to allow it to be passed into the CNN model in the
numerical form: label encoding (Figure 2B), one-hot encoding
(Figure 2C; Goh et al., 2017), and embedding (Figure 2D).
Label encoding involves assigning each nucleotide its own
unique ID (A->0, C->1, etc.) This imposes an ordering on the
nucleotide sequences that may have implications for the neural
network learning (Figure 2B). This technique was implemented
using the Scikit-learn LabelEncoder package for the Python
programming language. We also tried one-hot encoding the
dataset by assigning each nucleotide its own bit encoded string
(A -> [0,0,0,0,1], C-> [0,0,0,1,0]) (Figure 2C). This tends to be
a favorable preprocessing function for weight-based classifiers
because no artificial ordering is imposed on the samples. This
technique tends to be the default representation choice for
categorical variables due to how it is interpreted. Because
each nucleotide gets its own index in a 5 bit string, a 1 in any
particular index means that nucleotide is present in that location.
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FIGURE 1 | The schematic workflow diagram of the CNN approach employed in this study. To determine the optimal architecture, we performed a grid search over a
total of 72 different neural network architectures. These 72 architectures consisted of between 1 and 3 convolutional layers and 1–3 fully connected layers following.
The number of nodes in each of these layers was also varied between 2 and 256 in powers of 2. The simplest architecture covered in this search contains 1
convolutional layer with 2 filters feeding into 1 fully connected layer with 2 nodes, and the most complex would have 3 convolutional layers feeding into 3 fully
connected layers, all containing 256 nodes.
For example, since A->[0,0,0,0,1], this can essentially be read
as “There are 0 ‘n,’ 0 ‘g,’ 0 ‘t,’ 0 ‘c,’ and 1 ‘a’ nucleotides present
at this location.” Since the one-hot encoding preprocessing
technique lengthens the string, the resulting dimensionalities
were (2, 105), (2, 505), (2, 1005), (2, 5005), and (2, 50005),
respectively. The final preprocessing technique employed for
the DNA sequences involved learned embeddings created with
the word2vec algorithm (Mikolov et al., 2013). This technique
analyzes the sequential context of the nucleotides assigning
them a numeric representation in vector space. Using this
representation, the nucleotide segments with similar meaning
in the word2vec model would yield similar vectors in an N-
dimensional representation. This technique was implemented
using the Word2Vec model from the genism library for the
Python programming language. Since the vocabulary in this
application is fairly small, consisting of only 5 bit components,
we chose to convert the nucleotide to 2 dimensional vectors
which is sufficient to effectively encode this set. This resulted in
the input sizes (2, 42), (2, 202), (2, 402), (2, 2002), and (2, 20002),
respectively (Figures 1, 2). The implementation and execution
of these three preprocessing techniques provides adequate and
efficient nucleotide representations for the CNN classifier.
Machine Learning Models
We used and compared performance of tree based classifiers and
DL/CNN machine learning models. For the tree based methods,
we used previously established protocol for obtaining hyper-
parameters (Agajanian et al., 2018). The model training and
tuning was done using Scikit-learn free software machine
learning library for the Python programming language
(Pedregosa et al., 2011; Biau, 2012). The Keras framework
was used for training, validation and testing of CNN models
(Erickson et al., 2017). We initially held out 20% of the data
in a stratified manner as a testing set so that it had the same
distribution of passengers/drivers as the total dataset. We then
used the remaining 80% of the dataset as the training set to learn
and tune its hyper-parameters. To choose between the hyper-
parameters attempted, we test our model out on unseen data
so that we have an unbiased estimate of its performance. To do
this, we performed 3-fold cross validation, splitting the training
set up into three equal sized portions. The model trains on two
of them, and makes predictions on the third. This is repeated
three times so that each of the three portions has been predicted
on. A workflow diagram of the CNN approach (Figure 1) was
carefully engineered to determine the optimal architecture. For
this, we performed a grid search over a total of 72 different
neural network architectures. These 72 architectures consisted
of between 1 and 3 convolutional layers and 1–3 fully connected
layers following. The number of nodes in each of these layers
was also varied between 2 and 256 in powers of 2. The simplest
architecture covered in this search contains 1 convolutional layer
with 2 filters feeding into 1 fully connected layer with 2 nodes,
and the most complex would have 3 convolutional layers feeding
into 3 fully connected layers, all containing 256 nodes. The ReLU
activation function was used, which returns max (0, X). All 72
different architectures (Table 1) were tested using this cross-
validation algorithm and the architecture that had the highest
F1 score across all 3-folds was chosen. Our neural networks
were trained for 100 epochs, which means that they will pass
through the entire dataset 100 times to complete their training.
In between each epoch, the model recorded its predictions on
the validation fold, and the epoch with the best performance
on the validation set was recorded. Dropout was applied in
between layers, so that inputs into a layer are randomly set to
0 with a certain probability. This prevents the neural network
from overfitting, forcing it to learn without random features
present. The best architecture was used for predictions on the
test set.
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FIGURE 2 | Preprocessing of the nucleotide information for CNN machine learning of cancer driver mutations. Two different preprocessing techniques were then
applied to the dataset to allow it to be passed into the CNN model in the numerical form: label encoding and one-hot encoding. (A) A schematic diagram of window
sliding protocol. To represent the original nucleotide and its mutated version, two nucleotide sequences are placed on top of each other, one containing the original
string, and the other contained the mutated version. This representation allows to utilize the sliding window format of the CNN models. (B) A schematic diagram of
label encoding preprocessing protocol. Label encoding assigns each nucleotide its own unique ID (A->0, C->1 etc.) This imposes an ordering on the nucleotide
sequences. (C) A schematic diagram of one hot encoding preprocessing protocol. One-hot encoding assigns each nucleotide its own bit encoded string (A ->
[0,0,0,0,1], C-> [0,0,0,1,0]). This tends to be a favorable preprocessing function for weight-based classifiers because no artificial ordering is imposed on the samples.
(D) A schematic diagram of embedding preprocessing scheme created with the word2vec algorithm.
TABLE 1 | The parameters of displayed CNN architectures in classification of
cancer driver mutations.
Architecture # Layers # Nodes per layer
0 2 32,2
1 3 16,8,2
2 3 16,16,2
3 3 32,16,2
4 3 32,8,2
5 3 64,32,2
6 3 64,16,2
7 4 64,64,16,2
8 4 128,64,16,2
9 4 128,64,32,2
10 5 128,64,32,16,2
To assess the performance of each model, Accuracy, Recall,
Precision, and F1 score were calculated to measure the
performance of classification models. These parameters are
defined as follows:
Accuracy =
TP + TN
all
; Precision =
TP
TP + FP
(1)
Recall =
TP
TP + FN
; F1 = 2
Precision ∗ Recall
Precision+ Recall
(2)
True Positive (TP) and True Negative (TN) are defined as the
number of mutations that are classified correctly as driver and
passenger mutations, respectively. False Positive (FP) and False
Negative (FN) are defined as the number of mutations that
are misclassified into the other mutational classes. Precision is
defined as the amount of positive samples the model predicts
correctly (true positives) divided by the true positives plus the
false positives. Recall is defined as true positives divided by
true positives plus false negatives. The model performance was
evaluated using receiver operating characteristic area under the
curve. The receiver operating curve (ROC) is a graph where
sensitivity is plotted as a function of 1-specificity. The area under
the ROC is denoted AUC. The sensitivity or true positive rate
(TPR) is defined as the percentage of non-neutral mutations that
are correctly identified as driver mutations:
Sensitivity = TPR =
TP
TP + FN
(3)
The specificity or true negative rate (TNR) is defined as
the percentage of mutations that are correctly identified
as passengers:
Specificity = TNR =
TN
TN + FP
(4)
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In combination, these scores allow us to differentiate models
by providing evaluation options to properly asses a model’s
performance. We relied on the F1 score, precision and recall as
the primary discriminatory measures that can assess the quality
of classification more reliably than accuracy. Under this data
distribution, a model that only predicted passenger would yield
an accuracy of 66.95%, but an F1 score of 0. In the case that two
model’s exhibited the same F1 score, we used the AUCmeasure to
break the tie. The AUC measure is derived from the fact that the
output of these classificationmodels is a likelihood value between
0 and 1. A powerful classifier learns a likelihood function that
consistently maps instances of the negative class to likelihoods
lower than the positive class. A model that is reliable able to
do this would receive an AUC of 1, whereas a model that only
predicted the negative class would also receive an AUC of 0.
Bimolecular Simulations of Cancer
Mutation Effects: Rigidity Decomposition
and Protein Stability Analysis
We used FIRST (Floppy Inclusion and Rigid Substructure
Topography) approach (Jacobs et al., 2001; Rader et al., 2002;
Chubynsky and Thorpe, 2007) and the Python-based Constraint
Network Analysis (CNA) interface (Hespenheide et al., 2002;
Kruger et al., 2013; Pfleger et al., 2013a,b) to analyze partition
of rigid and flexible regions in a set of protein kinases with the
predicted cancer driver mutations. The employed parameters
are consistent with our previous studies of protein kinases
(Stetz et al., 2017). Protein stability computations that evaluated
the effect of cancer driver mutations on the functional forms
of the ErbB kinases were performed using CUPSAT (Cologne
University Protein Stability Analysis Tool) (Parthiban et al., 2006,
2007). This approach was successfully adopted for the energetic
analysis of cancer mutation hotspots (Dixit et al., 2009; Dixit
and Verkhivker, 2011). We also employed the Foldx method
(Guerois et al., 2002; Schymkowitz et al., 2005; Tokuriki et al.,
2007; Van Durme et al., 2011) that allows for robust assessment
of mutational effects on protein stability. These calculations were
done with the user interface for the FoldX force field calculations
(Schymkowitz et al., 2005) implemented as a plugin for the
YASARA molecular graphics suite (Van Durme et al., 2011).
Protein Structure Network Analysis
For network-based analysis, a graph-based representation of
protein structures is employed in which residues are treated
as network nodes and inter-residue edges represent residue
interactions (Sethi et al., 2009; Vijayabaskar and Vishveshwara,
2010; Stetz and Verkhivker, 2017). NAPS approach (Chakrabarty
and Parekh, 2016) was used for construction of the residue
interaction networks and subsequent residue-based network
centrality analysis. For our analysis, an interaction strength-
based graph representation of protein structures was used in
which a residue is considered as node in the network and
an edge is constructed if the interaction strength between
two residues is more than the threshold of 4%. The pair of
residues with the interaction Iij greater than a user-defined
cut-off (Imin) are connected by edges and produce a protein
structure network graph for a given interaction cutoff Imin. The
interaction strength Iij is considered as edge weight. The edges
in the residue interaction networks were weighted based on the
defined interaction strength and dynamic residue correlations
couplings (Sethi et al., 2009; Stetz and Verkhivker, 2017). Using
the constructed protein structure networks, the residue-based
betweenness parameters were also computed with the NAPS
server (Chakrabarty and Parekh, 2016). The betweenness of
residue i is defined to be the sum of the fraction of shortest paths
between all pairs of residues that pass through residue i:
Cb(ni) =
N∑
j<k
gjk(i)
gjk
(5)
gjk denotes the number of shortest geodesics paths connecting
j and k, and gjk(i) is the number of shortest paths between
residues j and k passing through the node ni. Residues with high
occurrence in the shortest paths connecting all residue pairs have
a higher betweenness values. For each node n, the betweenness
value is normalized by the number of node pairs excluding n
given as (N − 1)(N − 2)/2, where N is the total number of nodes
in the connected component that node n belongs to.
RESULTS
Deep Learning Classification of Cancer
Driver Mutations From Nucleotide
Information
We began with an attempt to recapitulate our predictions by
using various DL/CNN architectures informed by raw nucleotide
sequence data evaluated the ability to make predictions based
solely on raw genomic information. The inclusion of the three
different preprocessing techniques allowed us to select the most
informative representation of the nucleotides. The one hot
encoded sequences yielded the model with the best performance,
and for clarity of presentation we report only the dimensions and
performance of the one hot encoded model. This preprocessing
model resulted in input matrices of size (2, 105), (2, 505), (2,
1005), (2, 5005), and (2, 50005) corresponding to the different
window sizes (10, 50, 100, 500, 1,000) surrounding the original
nucleotide. It is worth noting that the embedding algorithm
also learned meaningful representations of the nucleotides.
The missing place indicator, “n,” was predictably separated
from the original nucleotides, which were arranged in 2 neat
clusters (Figure 2D). Cluster 1 consisted of the adenine and
tyrosine nucleotides, and cluster 2 consisted of the guanine and
cytosine nucleotides. These two clusters are easily identified due
to the fact that their constituent components are very close
to each other while simultaneously being far away from the
other cluster.
We employed 72 different DL architectures (Table 1) and
the results for the window size of 10 are presented since they
revealed more variance (Figure 3). The figures below display
the 10 best performing models out of the 72 attempted. The
training accuracy continued to increase for the duration of
training (Figure 3A), while on the validation testing set of
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cancer mutations, the best DL/CNN architecture achieved an
average validation accuracy of 86.68% with an F1 score of
0.61 (Figure 3B). Interestingly, we found that the DL model
seemed to learn early on, overfitting with each successive epoch
(Figure 3B). In fact, the model achieved its highest validation
accuracy on the first epoch, and proceeds to decline as learning
proceeds in subsequent epochs. Furthermore, the AUC score
of the model as well as the F1 score consistently stayed the
same throughout all of the process. This is further contextualized
by the tree based method’s performance on the same dataset.
The GBT classifier exhibited an F1 score of 0.57 with an
average validation accuracy of 66.59%, and the RF classifier
exhibited an F1 score of 0.58 and an average validation accuracy
of 69.86%. We analyzed predictions by the DL/CNN model
by assigning the predicted values for the entire dataset as a
separate new feature termed DL score. Although we probed a
variety of different architectures and several nucleotide-encoding
protocols, a direct brute-force application of DL/CNN models
to predict driver mutations only as a function of surrounding
nucleotides appeared to be challenging. As a result, we suggested
that a diverse set of more informative features may be required
to recapitulate the level of robust performance achieved in our
earlier work with sequence-based conservation and functional
features (Agajanian et al., 2018).
We first used the RF classifier on the cancer mutation
dataset with functional and conservation features obtained from
dbWGFP server and adopted in our previous study (Agajanian
et al., 2018). A database of human non-synonymous SNVs
(dbNSFP) was developed as a one-stop resource for analysis of
disease-causing mutations (Liu et al., 2011, 2013, 2016; Dong
et al., 2015; Wu et al., 2016) storing 8.58 billion possible
human whole-genome SNVs, with capabilities to compute
a total of 48 functional prediction scores for each SNV,
including 32 functional prediction scores by 13 approaches,
15 conservation features from 4 different tools including
ensemble-based predictors RadialSVM, LR, and MSRV scores.
The initially selected features were obtained from dbWGFP
web server of functional predictions for human whole-genome
single nucleotide variants that provided 32 functional prediction
scores and 15 evolutionary features (Agajanian et al., 2018).
Functional prediction scores refer to scores that predict the
likelihood of a given SNV to cause a deleterious functional
change in the protein, and evolutionary scores refer to scores
providing different conservation measures of a given nucleotide
site across multiple species (Supplementary Table S1). Some of
the score features (SIFT, PolyPhen, LRT, Mutation Assessor,
MutationTaster, FATHMM, RadialSVM, LR, MSRV, and SinBaD)
can be applied only to SNVs in the protein coding regions,
while other scores (Gerp++, SiPhy, PhyloP, Grantham, CADD,
and GWAVA) can evaluate SNVs spreading over the whole
genome (Supplementary Table S1). The ensemble-based scores
RadialSVM and LR are integrated features that used machine
learning approaches to combine information from 10 individual
component scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR,
Gerp++, MutationTaster, Mutation Assessor, FATHMM, LRT,
SiPhy, PhyloP) (Agajanian et al., 2018).
In this baseline experiment we evaluated feature performance
of 32 input features on the expanded dataset (Figure 4A).
Similar to our previous investigation (Agajanian et al., 2018),
we found that the ensemble-based scores LR and RadialSVM
considerably overshadowed the contributions of other features
(Figure 4). By adding DL score to the original 32 features, we
applied the RF model for predicting cancer driver mutations
with this expanded set of features. The first question was to
analyze feature importance of the RF model with the DL score
included and determine whether the nucleotide-based scoring
feature can contribute to the prediction performance in a
meaningful and appreciable way (Figure 4). In the second round
of RF classification experiments, we added DL score to the
original list of 32 features (Figure 4B). Strikingly, the DL score
ranked third following the ensemble-based LR and RadialSVM
scores (Figure 4B). Moreover, it was evident that these
three feature scores completely dominated feature importance
distribution, with the DL score contributing almost as much
FIGURE 3 | The average accuracy of CNN model using exclusively nucleotide information. (A) Average accuracy across all 3-folds on an epoch by epoch basis on
the training set with the sliding window size = 10. (B) Average accuracy across all 3-folds on an epoch by epoch basis on the validation set with the sliding window
size = 10.
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FIGURE 4 | Feature importance of the RF machine learning model on the cancer mutation dataset. The dataset consists of functionally validated 6,389 cancer driver
mutations and 12,941 passenger mutations. The initially selected features for RF predictions were obtained from dbWGFP web server (Wu et al., 2016) of functional
predictions for human whole-genome single nucleotide variants (Supplementary Table S1). The test set contained 20% of the samples from the original dataset,
ensuring that the distribution of drivers and passengers was equivalent to that of the original dataset. The training set was subjected to recursive feature elimination
process, resulting in a final dataset of 32 features. (A) Feature importance of 32 functional and sequence conservation features with DL score feature produced by
CNN model excluded. (B) Feature importance of 33 features with the DL score included in the RF classification. The feature importance values are shown in blue filled
bars and annotated. Feature importance is measured using the information value and weight of evidence criteria.
as the ensemble-based RadialSVM feature (Figure 4B). Quite
remarkably, the DL-based score derived by CNN exclusively
from primary nucleotide information can deliver significant
information content and enrich predictions.
Using Spearman’s rank correlation coefficient, we computed
the pairwise correlations between different prediction scores
(Figure 5). In this analysis, we found that the two dominant
feature scores RadialSVM and LR are only moderately correlated
with DL score, with the correlation coefficient of 0.486 and
0.423, respectively. Interestingly, RadialSVM and LR scores are
more significantly correlated, suggesting that these ensemble-
based features could be complementary with the nucleotide-
based DL score. Accordingly, we argued that a combination
of these dominant and yet complementary scores may allow
for feature reduction and more robust performance of the RF
classification models.
Integration of CNN Predictions With
Ensemble-Based Features in Classification
Models of Cancer Driver Mutations
Based on these findings, we evaluated feature selection again
aiming to recreate the same accuracy with only 8 features:
RadialSVM score, LR score, DL score, GerpRS, LRT score,
verPhyloP, SiPhy score, GerpN (Figure 6A). The RF model
with only 8 features produced a similar ranking in which
the ensemble-based scores and DL score contributed the most
(Figure 6A). Other contributing features included evolutionary
conservation scores derived from multiple sequence alignments
and reflecting functional specificity, such as GerpRS (Davydov
et al., 2010), SiPhy (Garber et al., 2009), and PhyloP (Garber
et al., 2009) also showed appreciable information score values
(Figure 6A). We then tested the performance of the RF model
FIGURE 5 | The pairwise Spearman’s rank correlation heat map between
different prediction scores. The heat map of pairwise Spearman’s rank
correlation coefficients is shown for top 8 ranking features in the RF
classification of cancer mutations with a total of 33 features with DL score
included. The high ranking features include ensemble-based RadialSVM, LR
scores along with DL score produced by CNN model solely from the raw
nucleotide information.
and feature importance by performing machine learning of
cancer driver mutations using only 3 top features (Figure 6B).
The predictive performance of the RF models with different
set of features was examined using area under the curve (AUC)
plots (Figure 7). First, we examined difference in the AUC
curves for RF-based classification with 32 functional features
and with additional DL score (Figure 7A). The results showed
a very similar high-level prediction performance with AUC =
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FIGURE 6 | Feature importance of the RF model on the cancer mutation dataset with the reduced number of features. (A) Feature importance ranking based on RF
classification with only 8 most informative features. (B) Feature importance ranking based on RF classification with only 3 top features that included ensemble-based
RadialSVM, LR scores, and DL score produced by CNN model. The feature importance values are shown in blue filled bars and annotated. Feature importance is
measured using the information value and weight of evidence criteria.
0.95–0.96. It is worth noting that due to high AUC value for
RF classification with 32 informative functional features, the
addition of DL could not significantly enhance it. However, we
showed that this nucleotide-derived predictor score provides an
additional information content and is complementary to the
ensemble-based RadialSVM score and LR score. In this context,
it was instructive to observe that addition of DL score may
marginally improve separation between TPR and FPR at higher
values of these parameters (Figure 7A).
Strikingly, RF learningmodel that relied on only 3 top features
(RadialSVM score, LR score, and DL score) yielded AUC =
0.94, thereby showing that these features may be sufficient to
achieve robust classification of cancer driver mutations on a
fairly large dataset of somatic mutations employed in this study.
Combined with the findings that DL score only weakly correlated
with the ensemble-based scores, we concluded that unexpectedly
few highly informative parameters can achieve high level of
performance (Figure 7).We then tested several machine learning
models including RF, GBTs and support vector machine (SVM)
on the dataset with the top 8 features to benchmark performance
against the original RF model with 32 features (Agajanian et al.,
2018). The performance of classification models was carefully
assessed (Table 2). All methods achieved a high classification
accuracy of∼90%. The sensitivity values were higher for the SVM
and RFmodels, but all methods yielded similar high performance
classification on the dataset with only limited number of major
features that included DL score (Table 2).
To summarize, our results supported the notion that machine
learning-derived ensemble functional predictors may play a
central role in classification of cancer driver mutations. The
central finding of these machine learning experiments was that
combination of ensemble-based features and DL score derived
by CNN model from nucleotide information are complementary
and when combined can yield classification accuracy comparable
and often exceeding the one obtained with a full set of features.
The important lesson from this analysis is that integrated high-
level features derived by machine learning approaches from
primary nucleotide and protein sequence information may
be sufficient to predict an important functional phenotype.
Although structure-derived features and other functional scores
contribute to feature importance ranking and tightly linked
with the mutational phenotype, the success of machine learning
tools in deciphering predictive features from primary sequence
information is encouraging and should be further explored in
other applications.
Leveraging Machine Learning Predictions
in Structure-Functional Analysis of
Molecular Signatures of Driver Mutations
in Oncogenic Protein Kinases
Machine learning driver/passenger classifications typically
consider activating, inactivating and inhibitory (or resistant)
mutations as drivers, often leaving aside a more detailed
characterization and assignment of driver positions. Direct
predictions of these specific classes may not be adequately
suited for machine learning tools due to smaller datasets. To
expand our predictions and aim at extracting a more granular
functional information about driver mutations, we conducted
rigidity decomposition simulations and analyzed conformational
flexibility of the predicted driver positions in protein kinase
genes. The objective of this analysis was to facilitate functional
validation and interpretation of machine learning results
through coarse-grained biophysical simulations as an effective
post-processing tool of machine learning classification. In
fact, the proposed simulation analysis of mobility at the driver
positions allows to expand classification of driver mutations
further and characterize activating drivers. Previous studies
have suggested that conformational mobility of many oncogenic
kinases may be linked with preferential localization of activating
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FIGURE 7 | The ROC plots of sensitivity (TPR) as a function of 1-specificity, where specificity (TNR). (A) The ROC curves for overall performance of the RF model with
32 functional features excluding DL score (in green) and 33 features that included DL score (in red). (B) The ROC curves for the RF model with all 33 features (in green)
and with the top 3 performing features that included LR score, Radial_SVM score, and DL score (in red). Higher AUC score indicates better performance. These plots
illustrated a comparative performance of machine learning models for top prediction scores.
TABLE 2 | The relative performance metrics and statistics of various machine
learning models in classification of cancer driver mutations with the top 8 features.
Boosted trees SVM Random forest
Accuracy 0.896 0.890 0.896
F1 score 0.900 0.890 0.900
Precision 0.900 0.890 0.900
Recall 0.900 0.890 0.900
True positive rate 0.850 0.949 0.857
False positive rate 0.112 0.797 0.123
True negative rate 0.115 0.016 0.107
False negative rate 0.913 0.748 0.907
cancer mutations in flexible functional regions (Paladino et al.,
2015; Kiel et al., 2016; Stetz et al., 2017).
We examined flexibility of specific functional regions targeted
by driver mutations in oncogenic protein kinases and probed
functional propensity of these drivers to promote transitions to
constitutively active states. The primary focus of this analysis is
on the family of the ErbB protein tyrosine kinases (Lemmon and
Schlessinger, 2010; Roskoski, 2014). A number of human cancers
are associated with mutations causing the increased expression
of the ErbB kinases. A large number of activating and drug
resistance EGFR mutations have been extensively studied at the
molecular and functional levels (Paez et al., 2004; Kobayashi et al.,
2005; Zhou et al., 2009; Eck and Yun, 2010). Oncogenic kinase
mutants are known to act by destabilizing the inactive dormant
kinase form while promoting conformational transitions and
stabilization of a constitutively active kinase state—a salient
functional characteristic linked with the initiation or progression
of cancer (Carey et al., 2006; Wang et al., 2011). We used the
crystal structures of the EGFR, ErbB2, ErbB3, and ErbB4 kinases
that constitute this family to perform rigidity decomposition
and then align the positions of the predicted cancer driver
mutations with the structural mobility maps (Figure 8). We
examined how the predicted driver mutations for ErbB protein
kinases are distributed on the rigidity/flexibility map of the
catalytic core and whether the dynamic preferences of mutational
sites can be linked with their primary function as activating
drivers. To explore these questions, we examined the predicted
cancer driver mutations for the ErbB kinase family. Structural
mapping of these cancer mutations onto the crystallographic
ErbB conformations showed that activating driver mutations are
preferentially localized in the flexible regions and target positions
where they can readily promote conformational changes to
the active form without severely compromising thermodynamic
stability (Figure 8).
To quantify these arguments further, we also characterized
the free energy differences between wild-type and cancer-
driver mutations for the ErbB proteins in both inactive and
active kinase forms (Figure 9). Since both CUPSAT and FoldX
approaches yielded similar results, we illustrated our findings by
presenting FoldX-derived protein stability changes (Figure 9).
The results of this simulation-driven functional classification of
predicted driver mutations were compared with the biochemical
and mutagenesis data. The analysis of driver mutations in
EGFR confirmed that L858 and L861 positions target flexible
regions as can be manifested by classical activating driver
mutations L858R and L861Q (Littlefield and Jura, 2013; Red
Brewer et al., 2013). The energetics of these activating drivers
is consistent with a common mechanism of the constitutive
activation of kinases by driver mutations (Figure 9A). This
mechanism reflects a combined effect of activating mutations
producing a more significant destabilization of the inactive
state as compared to the active state, triggering shift of the
thermodynamic equilibrium toward the active conformation.
We found that some EGFR mutations such as T854A are
mapped onto more stable regions of the kinase (Figure 8A) and
showed similar destabilization in the inactive and active forms.
Accordingly, this predicted cancer driver mutation is likely not
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FIGURE 8 | Structural maps of rigidity decomposition and mobility signatures of cancer mutation drivers in the ErbB protein kinases. Structural mapping of rigidity and
flexibility regions in the crystal structure of EGFR (pdb id 1XKK) (A), crystal structure of ErbB2 kinase (pdb id 3PP0) (B), crystal structure of ErbB3 kinase (pdb id 3KEX)
(C), and crystal structure of ErbB4 kinase (pdb id 3BBT) (D). Crystallographic conformations are colored using a color range from red (highest flexibility) to blue
(highest rigidity). The positions of predicted in machine learning cancer driver mutations are shown in spheres (colored according to their mobility level) and annotated.
activating but rather may be attributed to inhibitory or resistant
mutations. Indeed, the recent experimental studies showed that
T854A mutation is the acquired mutation causing resistance
to known drugs (Bean et al., 2008). Another EGFR mutation
V769M/L showed an intermediate level of mobility (Figure 8A)
and greater stabilization of the active state. These results are
in line with recent functional experiments showing that EGFR-
V769Mmutation is indeed activating that may explain the role of
this driver mutation in the development of multiple lung cancers
in a pool of lung cancer patients (Deng et al., 2018).
The positions of almost all predicted driver mutations in
ErbB2 kinase target highly flexible regions and can be assigned
in our model to activating driver mutations (Figures 8B, 9B).
Our previous biophysical simulations and network analysis of
activation mechanisms in the ErbB proteins similarly indicated
that almost all oncogenic ErbB2 variants are localized in
the mobile αC-β4 loop and highly dynamic in their inactive
states promoting transition to the active form and causing an
uncontrollable activity (James and Verkhivker, 2014). These
findings are consistent with the experimental studies (Fan et al.,
2008; Aertgeerts et al., 2011). While the majority of somatic
mutations in the EGFR and ErbB2 kinases increase the kinase
activity, a number of the classified ErbB4 cancer mutants have
been shown to inhibit or reduce the kinase activity (Tvorogov
et al., 2009). In particular, some cancer-associated mutations
of ErbB4 can promote loss of ErbB4 kinase activity as these
alterations weaken the important functional interactions in the
catalytic core and may interfere with the protein stability.
According to experimental data, some cancer mutations have
only minor or no effect on kinase activity (V696I, E785K,
A748S, P757Q, P829Q, and T901M), while K726R abolishes
kinase activity and D818N and D836Q are known as kinase-
dead mutations (Tvorogov et al., 2009). We found that predicted
cancer driver mutations are mapped onto more stable regions
in ErbB4, owing to the greater rigidity of this catalytic domain
(Figures 8D, 9D). Accordingly, the respective driver mutations
cannot function as activating but rather may cause significant
distortions of the kinase structure, causing abolishment of kinase
activity which is the functional signature ofmost cancer drivers in
ErbB4 kinase. The performed simulation-driven post-processing
of machine learning predictions facilitated in silico functional
characterization of cancer mutations and allowed to properly
assign activating or inhibiting phenotypic effects to a pool of
pathogenic kinase variants.
To provide more quantitative insights, we used the predicted
cancer mutations in the ErbB kinases and conducted protein
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FIGURE 9 | Protein stability analysis of the predicted cancer driver mutations. Protein stability differences calculated between the wild-type and mutants for predicted
cancer driver mutations in the ErbB kinases using FOLDx approach. Protein stability changes induced by cancer driver mutations in the inactive and active states of
EGFR kinase (A), ErbB2 kinase (B), ErbB3 kinase (C), and ErbB4 kinase (D). Positive values of protein stability changes correspond to destabilizing mutations.
structure network analysis to identify whether positions of
deleterious mutations would overlap with the global mediating
nodes in the interaction networks. The betweenness of a
residue node is defined as the number of shortest paths that
can go through that node, thus estimating the contribution
of the node to the global communication flow in the
system. High betweenness nodes can influence the spread of
information through the network by facilitating, hindering,
or altering the communication between others. According to
our hypothesis, cancer mutations may preferentially target the
essential mediating residues with a high centrality that play an
important role in activity and signaling of protein kinase genes.
The centrality analysis revealed important differences in the
distribution of mediating centers in the ErbB kinase structures
(Figure 10). We particularly observed that the betweenness of
the active form of EGFR (Figure 10A) and ErbB4 (Figure 10D)
was on average higher than for the inactive states. Importantly,
the location of the properly classified EGFR mutations with
the highest oncogenic potential (L858R, T790M, L838V, V742A,
V851A, I853T) corresponds to some of the high centrality
peaks of the profile (Figure 10A). In addition, these residues
showed appreciable differences in the betweenness values
between the inactive to the active states, as the residue
centrality in these positions typically increased in the functional
active form (Figures 10A,D). These findings suggested that
a number of key activating mutations in the ErbB kinases
target mediating sites of global allosteric communication in the
protein structures. We believe that by adding this significant
additional component to our study, we have been able to further
quantify and explain the protein rigidity/flexibility analysis of
predicted cancer mutations in the kinase genes. In our view, by
complementing machine learning predictions with the structural
and network-based analyses we can obtain useful insights
into mechanisms underlying effects of cancer mutations and
also identify limitations of classification models and ways to
improve interpretability and trustability of machine learning
model approaches.
DISCUSSION
As large-scale biological data are available from high-throughput
assays, and methods for learning the thousands of network
parameters have matured, we can now assess feasibility and
practicality of using specialized neural network architectures as
classification tools for recognizing cancer-causing variants and
associated cancer types. Given rapid proliferation and increasing
popularity of deep learning tools to address various biological
problems, there are several fundamental questions arising in the
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FIGURE 10 | The residue-based betweenness profiles of the ErbB kinase structures. The residue betweenness (residue centrality) profiles for the inactive and active
crystal structure states of EGFR (A), ErbB2 (B), ErbB3 (C), and ErbB4 kinases (D). For ErbB2 and ErbB3 only crystal structures of the inactive-type states were
available for the analysis. The positions of somatic mutations predicted by machine learning experiments are shown in maroon-colored filled triangles, and residue
positions corresponding to the hydrophobic spine residues are shown in orange-colored filled triangles. Protein kinase activation is controlled by two networks of
mostly hydrophobic residues that form a regulatory spine (R-spine) and a catalytic spine (C-spine). The EGFR R-spine residues include L777 from the β4-strand, M766
from the C-terminal end of the αC-helix, F856 of the DFG motif in the activation segment, H835 of the HRD motif of the catalytic loop, and D896 of the αF-helix.). The
R-spine residues in ErbB2 are M774, L785, F864, H843, and D904. The R-spine residues in ErbB3 are I744, L755, F843, H813, and D874. The R-spine residues in
ErbB4 are M747, L758, H816, F837, and D877.
context of classification of cancer driver mutations. Will deep
learning make all other models obsolete? Can deep learning
models achieve robust classification and recognition of cancer
driver mutations based solely on nucleotide information? What
is the role of many functional and structural predictors derived
from biophysical perspective in this context? In this work,
we have explored and integrated different machine learning
approaches for prediction and classification of cancer driver
mutations. We first explored the ability of CNN models to
identify and classify cancer driver mutations directly from raw
nucleotide sequence information without relying on specific
functional scores.
The results of this study have demonstrated that while CNN
models can learn high level features from genomic information
that has sufficiently high importance, accurate classification of
cancer mutation driver phenotype using exclusively nucleotide
data continues to be challenging. This problem is admittedly
more complex than the experimental design suggests, due to
the complex nature of protein interactions in the human body.
This experimental setup considered only the primary sequence
form of the nucleotides, which could only ever partially explain
the onset of cancer. The secondary, tertiary, and quaternary
form of these same strings would certainly contain more
information, due to the folding processes that occur in these
steps. Additionally, this technique ignores all of the possible
interactions that can be had with other structures in the body,
which further dilutes the informational value present in the
dataset. As such it’s unreasonable to assume that our solely
primary sequence based dataset would be able to explain all
of the variance present in a complex problem like determining
a single mutation’s level of effect on the onset of cancer.
The experimental inclusion of the different window sizes was
also an attempt to allow increasing numbers of surrounding
nucleotides to have an influence on our chosen mutation’s effect.
An obvious assumption here is that more nucleotides would
in fact bring in more information. This, however, proved not
to hold up as the only dataset that provided any significant
variance in performance was the window size = 10 dataset.
This suggests that more nucleotides only confuse the model and
disallow it from learning informative patterns. This problem
could possibly be combatted in future research by testing out
larger architectures.
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The benefits of integrating CNN-derived predictors obtained
from nucleotide information with protein sequence features,
evolutionary and functional scores were then carefully examined.
By exploring various encoding techniques and an array of
different CNN architectures, we have found that neural networks
can quickly learn an important functional signal, but can rarely
steadily improve the initial performance spike with the number of
additional epochs. The juxtaposition of monotonically increasing
training accuracy with monotonically decreasing validation
accuracy is a telltale sign of overfitting. This suggests that there
is only a small amount of useful information that can be learned
very early on, and subsequent epochs only cause the model to
learn noisy patterns that are only exhibited in the training set. It is
difficult to determine exactly what was learned by the model due
to the black box nature of neural networks, however due to the
short path to optimality it is safe to say that any learned concepts
cannot be overly complex. We have pursued a synergistic
strategy in which the prediction score generated by CNN
models was integrated with physics-based functional, structural
and evolutionary conservation features. The important lesson
of this analysis was the revelation that CNN-derived features
may be complementary to the ensemble-based predictors often
employed for classification of cancer mutations. These other
scores are not calculated from raw sequence based techniques,
which supports this DL score as a novel inclusion into a portfolio
of scores due to its unique derivation.
By combining deep learning-generated score with only two
main ensemble-based functional features, we were able to achieve
a high performance level for cancer driver mutations. The
robustness of this approach was verified by several traditional
machine learning classifiers, including RF, SVM, and GBTs. We
have found that integration of CNN-derived predictor score
with only several ensemble-based features can recapitulate the
results obtained with a large number of functional features and
improve performance in capturing driver mutations across a
spectrum of machine learning classifiers. Our findings have also
demonstrated that synergy of nucleotide-based deep learning
scores and integrated metrics derived from protein sequence
conservation scores can allow for robust classification of cancer
driver mutations with a reduced number of highly informative
features. This is an interesting and highly informative result,
as the law of parsimony holds for machine learning models
so simpler models with comparable performance are typically
preferred over their more complex counterparts. Part of this
model complexity includes the number of features that a model
relies on. As such a reduction in features is a universally positive
outcome. In addition to the improved quality of the model, it
also expands the universe of predictable nucleotides that are
available to us since we depend only on the presence of two
ensemble-based scores. The DL score can be derived for any
mutation with known coordinates so this is not a limiting factor.
In this respect our initial goal of expanding the nucleotides we
can make predictions for was partially achieved. This increase
in the generalization of these models facilitates the logical
conclusion of driver classification efforts, accurately classifying all
known nucleotides.
While machine learning approaches can often produce
robust and accurate predictors, the ultimate goal of research
is fundamental understanding of the underlying phenomena
which requires a mechanistic model of the world. In this context,
machine learning predictions are leveraged in biomolecular
simulations to enable analysis of cancer mutation mechanisms
and obtain a more specific information about an important
subset of cancer mutations, activating drivers. The results of
our investigation suggested that through integration of machine
learning classification and biomolecular simulations of cancer
mutations we can often validate the predictions and facilitate a
more detailed functional analysis of activating driver mutations.
These findings can provide insight and new angle to the problem
of interpretability of “black box” machine learning results. By
carefully inspecting predictions of machine learning models in
the context of dynamic and energetic signatures of mutational
sites for oncogenic protein kinases, this study offered instructive
strategy for simulation-based post-processing of machine
learning predictions and detailed functional specification of
cancer driver mutations. The proposed synergistic integration
of machine learning and biomolecular simulations into a
single computational platform allows to rapidly process large
datasets and make robust predictions on functionally significant
cancer drivers. The results of this study may also inform
and guide design of targeted and personalized therapeutic
agents combating a spectrum of mutational changes occurring
in cancer.
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